about
Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorderApomorphine and the dopamine hypothesis of schizophrenia: a dilemma?Regulation of dopaminergic function: an [18F]-DOPA PET apomorphine challenge study in humans.Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?Newer neurotransmitters in pain controlGPCR functional selectivity has therapeutic impact.The nature of dopamine dysfunction in schizophrenia and what this means for treatment.Dopamine receptor signaling and current and future antipsychotic drugs.Psychiatric symptoms of noradrenergic dysfunction: a pathophysiological view.Treatment mechanisms: traditional and new antipsychotic drugs.The dopamine D3 receptor, a quarter century later.PCP (phencyclidine): an update.New vistas in chronic schizophrenia.Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways.Evidence of brain dopamine deficiency in schizophrenia.The Many Faces of Apomorphine: Lessons from the Past and Challenges for the Future.Abnormal neural integration related to cognition in schizophreniaDetermination of Apomorphine in Tablets Using High Performance Liquid Chromatography with Electrochemical Detection
P2860
Q24652360-77425BB8-5A48-42B7-94A3-A4D48488B7CFQ28366409-7C34AE32-25B7-44AC-8C4C-C0F1444508B0Q33707670-A4A09465-86D6-47D7-B901-B8B9AACA044AQ35012574-3BD8D613-2B58-4326-ACEF-530A1992BC2DQ36836916-BA7B16A3-8533-410A-AD8A-542BCC12326AQ36880909-34669094-F91E-4109-8DA4-F4962A54F188Q37062793-6C5EB1B6-8BB6-4A2B-B391-D93065BE0D1DQ38058009-5467B752-2033-4327-8A42-1F8F8EFC77E3Q38174210-EF2C3A23-4910-4BF6-9091-B68E2A094B72Q38578382-7F4A790E-1C5F-43C1-B103-4F98E4CF8F35Q38947750-63E0852A-917D-4FA1-B20C-1BAF8FBFD2CAQ39294154-6DE2FA00-4960-45D5-9C05-E8759E0EC9FAQ39642548-94D67046-BD0F-4863-A905-91FEF411FA5EQ39749438-D087C47E-9F3D-442D-96D3-37E7F91B645BQ41031761-7F11CF0B-398F-4EBB-A7B2-B6B96BC731D4Q52316533-6B39BF08-C99B-42D8-941D-13ACC99E9B74Q57004084-3FAC5D2D-6D38-421A-898C-1734ACF35985Q58273393-7F4C1835-5FA2-4336-B82E-CBF5FDB01850
P2860
description
1978 nî lūn-bûn
@nan
1978 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1978 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1978年の論文
@ja
1978年論文
@yue
1978年論文
@zh-hant
1978年論文
@zh-hk
1978年論文
@zh-mo
1978年論文
@zh-tw
1978年论文
@wuu
name
Schizophrenic symptoms improve with apomorphine
@ast
Schizophrenic symptoms improve with apomorphine
@en
Schizophrenic symptoms improve with apomorphine
@nl
type
label
Schizophrenic symptoms improve with apomorphine
@ast
Schizophrenic symptoms improve with apomorphine
@en
Schizophrenic symptoms improve with apomorphine
@nl
prefLabel
Schizophrenic symptoms improve with apomorphine
@ast
Schizophrenic symptoms improve with apomorphine
@en
Schizophrenic symptoms improve with apomorphine
@nl
P2093
P356
P1433
P1476
Schizophrenic symptoms improve with apomorphine
@en
P2093
C A Tamminga
M H Schaffer
P356
10.1126/SCIENCE.347574
P407
P577
1978-05-05T00:00:00Z